CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $455,296 | +38.5% | 8,110 | +11.6% | 0.07% | +17.5% |
| Q1 2023 | $328,687 | +91.7% | 7,267 | +72.3% | 0.06% | +80.0% |
| Q4 2022 | $171,421 | +236.1% | 4,217 | +439.3% | 0.04% | +191.7% |
| Q3 2022 | $51,000 | +64.5% | 782 | +51.6% | 0.01% | +71.4% |
| Q2 2022 | $31,000 | -16.2% | 516 | -11.9% | 0.01% | 0.0% |
| Q1 2022 | $37,000 | +27.6% | 586 | +53.8% | 0.01% | +16.7% |
| Q4 2021 | $29,000 | +2800.0% | 381 | +6250.0% | 0.01% | – |
| Q3 2021 | $1,000 | 0.0% | 6 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | – | 6 | +50.0% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 4 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |